Juan C. Castillo
Sofia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Juan C. Castillo.
Europace | 2016
Francisco Carrasco; M Anguita; Martín Ruiz; Juan C. Castillo; Mónica Delgado; Dolores Mesa; Elías Romo; Manuel Pan; José Suárez de Lezo
AIMSnUse of cardiac pacing devices has grown in recent years. Our aim was to evaluate changes in epidemiology and clinical features of infective endocarditis (IE) involving pacemaker devices in a large series of IE over the last 27 years (1987-2013).nnnMETHODS AND RESULTSnFrom 1987 to December 2013, 413 consecutive IE cases were diagnosed in our hospital. During this period, 7424 pacemaker devices were implanted (6917 pacemakers, 239 implantable cardiac defibrillators, 158 resynchronization devices, and 110 resynchronization/defibrillator devices). All consecutive cases of IE on pacemaker devices were included and analysed. Infective endocarditis on pacemaker devices represented 6.1% of all endocarditis cases (25 patients), affecting 3.6/1000 of all implanted pacemakers. Its proportion increased from 1.25% of all endocarditis in 1987-1993 to 4.08% in 1994-2000, 7.69% in 2001-2007 and 9.32% in 2008-2013 (P < 0.01). Its incidence also increased from 1.4/1000 of all pacemaker implants in the period of 1987-1993 to 2.5/1000 in 1994-2000, 3.3/1000 in 2001-2007 and 4.5/1000 implanted devices in 2008-2013 (P < 0.05). Mean age of patients was 68 years, and 80% were male. Causative microorganisms predominantly were Staphylococci (84%: Staphylococcus aureus 48%, Staphylococcus epidermidis 36%). Rate of severe complications was high: persistent sepsis in 60% of cases, heart failure in 20%, and stroke in 12%. Device was removed in 19 patients (76%), mostly by surgery (18 of the 19 cases). Early mortality was 24% (33% of medically, 21% of surgically treated patients, P = 0.82).nnnCONCLUSIONnInfective endocarditis on pacemaker devices has shown an increasing incidence during the past decades, representing almost 10% of all IE in the last 6 years. This is a severe disease, with a high rate of severe complications and requiring removal of device in most cases. In spite of therapy, early mortality is high.
Clinical Cardiology | 2010
Manuel F. Jiménez-Navarro; Miguel A. Ramírez-Marrero; Manuel Anguita-Sánchez; Juan C. Castillo
Controversy exists concerning the influence of gender in the prognosis of patients with heart failure and no evidence is available from specific heart failure clinics.
American Journal of Cardiology | 2011
Martín Ruiz Ortiz; Elías Romo; Dolores Mesa; Mónica Delgado; Cristina López Ibáñez; M Anguita; Juan C. Castillo; José M. Arizón; José Suárez de Lezo
Our aim was to evaluate the effectiveness of oral anticoagulation (OAC) in patients aged ≥80 years with nonvalvular atrial fibrillation in daily clinical practice. From February 1, 2000 to June 30, 2009, we enrolled all patients aged ≥80 years with nonvalvular atrial fibrillation attended at 2 outpatient cardiology clinics of a tertiary care university hospital. The patients received antithrombotic treatment according to the recommendations from scientific societies and were prospectively followed, with major events (i.e., all-cause death, stroke, transient ischemic attack, peripheral embolism, severe bleeding) analyzed according to the treatment group (OAC vs no OAC). Of 269 patients included in the present study (87 men, mean age 83 ± 3 years), 164 received OAC (61%). After 2.8 ± 1.9 years of follow-up, the raw rates (per 100 patient-years) of embolic events (1.52% vs 8.30%, p <0.0001) and mortality (6.67% vs 10.94%, p = 0.04) were lower for patients receiving OAC, with a nonsignificant greater rate of severe bleeding (3.03% vs 1.25%, p = 0.14). The probability of survival free of major embolic or hemorrhagic events at the mean follow-up was greater for patients receiving OAC (82.27% vs 66.10%, p = 0.004). After adjustment for age, gender, coronary heart disease, and embolic risk, evaluated using the CHADS(2) score (congestive heart failure, 1 point; hypertension [blood pressure consistently >140/90 mm Hg or hypertension medication], 1 point; age ≥75 years, 1 point; diabetes mellitus, 1 point; previous stroke or transient ischemic attack, 2 points), only OAC was an independent predictor of embolic events (hazard ratio 0.17, 95% confidence interval 0.07 to 0.41, p <0.001). The CHADS(2) score (hazard ratio 1.32, 95% confidence interval 1.01 to 1.73, p = 0.04) and OAC (hazard ratio 0.52, 95% confidence interval 0.31 to 0.88, p = 0.01) were independent predictors of mortality. In conclusion, OAC according to the scientific societies recommendations is effective and safe in daily clinical practice, even in patients aged ≥80 years.
Echocardiography-a Journal of Cardiovascular Ultrasound and Allied Techniques | 2015
Martín Ruiz Ortiz; María Luisa Peña; Dolores Mesa; Mónica Delgado; Elías Romo; Marta Santisteban; Miguel Puentes; Amador López Granados; Juan C. Castillo; José M. Arizón; José Suárez de Lezo
Our objective was to evaluate the impact of asymptomatic acute cellular rejection (ACR) in left ventricular myocardial strain in heart transplant (HT) recipients by means of two‐dimensional speckle tracking echocardiography (2DSTE).
European Journal of Clinical Investigation | 2013
Martín Ruiz Ortiz; Cristina Ogayar; Elías Romo; Dolores Mesa; Mónica Delgado; M Anguita; Juan C. Castillo; José M. Arizón; José Suárez de Lezo
This study aimed to assess long‐term prognosis of stable coronary artery disease (sCAD) in patients aged ≥ 75 years and to identify clinical predictors of cardiovascular and overall mortality.
Journal of Clinical Hypertension | 2012
Martín Ruiz Ortiz; Elías Romo; Dolores Mesa; Mónica Delgado; Cristina Ogayar; M Anguita; Juan C. Castillo; José M. Arizón; José Suárez de Lezo
J Clin Hypertens (Greenwich). 2012;00:00–00 ©2012 Wiley Periodicals, Inc.
Revista Espanola De Cardiologia | 2012
Manuel Anguita; Juan C. Castillo; Martín Ruiz; Francisco Castillo; Manuel F. Jiménez-Navarro; Marisa Crespo; Luis Alonso-Pulpón; Eduardo de Teresa; Alfonso Castro-Beiras; Eulalia Roig; Remei Artigas; Antonio Zapata; Ignacio López de Ullibarri; Javier Muñiz
European Journal of Heart Failure Supplements | 2006
M. Anguita; Manuel F. Jiménez-Navarro; Juan C. Castillo
European Journal of Heart Failure Supplements | 2006
Juan C. Castillo; M Anguita; Fátima Esteban; Carmen Durán; Álvaro Martínez Moreno; Germán Hernández; Soledad Ojeda; J. Suarez Lezo
European Journal of Heart Failure Supplements | 2006
Juan C. Castillo; M. Anguita; Manuel F. Jiménez-Navarro